The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Armoneve 20 mg/10 mg prolonged-release tablets

20/10 mg/mg Prolonged-release tablet

Mundipharma Pharmaceuticals LimitedPA1688/017/005

Main Information

Trade NameArmoneve 20 mg/10 mg prolonged-release tablets
Naloxone hydrochloride dihydrate
Strength20/10 mg/mg
Dosage FormProlonged-release tablet
Licence HolderMundipharma Pharmaceuticals Limited
Licence NumberPA1688/017/005

Group Information

ATC CodeN02AA Natural opium alkaloids
N02AA55 oxycodone, combinations


Withdrawn Date29/10/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0102-061-024
Interchangeable List DocumentPDF of Interchangeable List
« Back